MedTrace Logo

Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection

NCT03388125 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2018-04-24

No results posted yet for this study

Summary

Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate Injection

Conditions

  • Bleeding Esophageal Varices

Interventions

DRUG

Injection Sclerotherapy

5% ethanolamine oleate group

DRUG

N-butyl-2-cyanoacrylate

N-butyl-2-cyanoacrylate injection group

Sponsors & Collaborators

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Mohamed Alsebaey, MD · Gastroenterology

  • Mohamed Abdelraouf, MD · Gastroenterology

  • Sherief Abd-Elsalam, MD · Hepatology and Gastroenterology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2017-08-01
Completion
2022-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03388125 on ClinicalTrials.gov